

VG Life Sciences, Inc.
447 Broadway, 2nd Floor
Unit 103
New York, NY 10013

April 2, 2024 - Supplemental Information Disclosure for VG Life Sciences, Inc. (the “Company”):

The Company has entered into a \$50,000.00 10% convertible promissory note agreement with an unrelated party (the “Note”). The Note matures February 13, 2025 and is convertible into the Company’s common stock at a price equal to 55% of the average closing price of the Company’s common stock during the 20 consecutive Trading Days prior to the date on which Holder elects to convert all or part of the Note.

The Company will continue to keep shareholders informed of developments.

The Company’s new official Twitter [X] account is @VGLSIR